JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

Check the time stamp on this data. Updated AI-Generated Signals for Protagonist Therapeutics Inc. (PTGX) available here: PTGX ...

Protagonist Therapeutics, Inc. (PTGX) stock price is 38.36 and Protagonist Therapeutics, Inc. (PTGX) 10-day simple moving average is 37.22. Protagonist Therapeutics, Inc. (PTGX) stock price is 38. ...

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in ...

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...